ClinicalTrials.gg
RecruitingNCT07338006Updated Jan 13, 2026

Chest Wall Reconstruction Cohort

An interventional study of chest wall reconstruction and Chest wall reconstruction in Chest Wall Tumor, Reconstructive Surgical Procedure and Malignancy, sponsored by University of Health Sciences Lahore. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by University of Health Sciences Lahore · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 years after the study started (first participant enrolled Jan 2021, registered Jan 2026).
  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Chest wall reconstruction following tumor or infection-related resections remains a challenging aspect of thoracic surgery, requiring restoration of structural stability and preservation of respiratory mechanics. While polymethyl methacrylate (PMMA) bone cement has long been used for rigid reconstruction, its limitations-including high cost, rigidity, infection risk, and interference with normal respiratory motion-pose challenges in resource-constrained settings. Twisted stainless steel wires offer a low-cost, flexible alternative that allows dynamic chest wall movement and easier adaptability in low- and middle-income countries such as Pakistan.

To compare postoperative outcomes, complications, and cost-effectiveness of chest wall reconstruction using twisted stainless steel wires versus PMMA bone cement over a two-year period (January 2025 - December 2026).

This prospective cohort study was conducted in the Department of Thoracic Surgery, Services Hospital, Lahore, a high-volume tertiary care and referral center. Patients undergoing chest wall reconstruction following resection for tumors, infections, or trauma were enrolled and divided into two groups based on the reconstruction technique used: Group A (twisted steel wires) and Group B (PMMA bone cement). Parameters assessed included postoperative pain (VAS scores), respiratory function, chest wall stability, complications (infection, wound dehiscence, prosthesis exposure), duration of hospital stay, readmission rate, and cost of reconstruction. Data were analyzed to compare clinical and functional outcomes between both cohorts.

Read the detailed description

Chest wall resection for tumors results in complex structural defects that require meticulous reconstruction to restore stability, protection, and respiratory function. The chest wall, composed of a combination of bony and soft tissue components, plays a crucial role in ventilation; thus, its reconstruction must achieve mechanical integrity while preserving physiologic mobility and minimizing postoperative morbidity.

Multiple techniques and materials have been developed for chest wall reconstruction, including synthetic meshes, titanium plates, and polymethyl methacrylate (PMMA) bone cement. PMMA remains widely used due to its moldability and compressive strength; however, its rigidity, low tensile strength, poor adhesion, and potential for thermal necrosis and infection limit its functional and clinical effectiveness. Furthermore, its high cost and non-dynamic properties make it less suitable in resource-constrained settings.

In contrast, twisted stainless steel wires (No. 05) offer a simple, durable, and cost-effective alternative. These wires provide robust mechanical support with dynamic flexibility, preserving normal respiratory motion and chest wall recoil. Recent advancements have demonstrated that wire-reinforced neorib configurations can achieve both tensile and compressive strength comparable to rigid prosthetics, while avoiding the static limitations of PMMA. Their affordability and availability make them particularly advantageous in low- and middle-income countries where economic feasibility dictates surgical decisions.

Recent studies have further explored biologic and synthetic prosthetic materials, microvascular flaps, and hybrid "biosandwich" techniques to optimize chest wall reconstruction outcomes. Nevertheless, data comparing simple, low-cost methods such as twisted steel wire constructs and PMMA-based reconstructions remain limited, particularly in regions with restricted access to advanced materials. In Pakistan, evidence is largely confined to isolated case reports, including a novel reconstruction of a neosternum using steel wires for recurrent sternal chondrosarcoma.

The present cohort study, conducted in the Department of Thoracic Surgery at Services Hospital, Lahore, aims to compare the outcomes of chest wall reconstruction using twisted stainless steel wires versus PMMA bone cement over two years from January 2025 to December 2026. By evaluating postoperative pain, respiratory function, chest wall recoil, and complication rates, this study seeks to provide evidence-based recommendations for the optimal reconstructive strategy in resource-limited healthcare environments.

02

Conditions studied

  • Chest Wall Tumor
  • Reconstructive Surgical Procedure
  • Malignancy

Keywords

  • Chest wall reconstruction
  • Bone cement
  • Stainless steel wire
  • Thoracic surgery
  • Postoperative pain
  • Functional outcomes
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 50 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of Health Sciences Lahore is the lead sponsor of 83 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged ≥18 years undergoing partial or full-thickness chest wall resection.
  • Defects requiring rigid or semi-rigid reconstruction involving two or more ribs or the sternum.

Exclusion criteria

Exclusion Criteria:

  • Patients with small defects managed by primary closure or soft tissue-only reconstruction.
  • Patients with concurrent major intrathoracic resections (e.g., pneumonectomy) may confound postoperative respiratory assessment.
  • Recurrent disease requiring revision reconstruction.
  • Patients unwilling or unable to provide consent or comply with follow-up.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Bone cement Arm

    This arm included patients that underwent chest wall reconstruction using bone cement

    Procedure: chest wall reconstruction

  • Experimental
    Steel wire arm

    This arm included patients that underwent chest wall reconstruction with steel wires

    Procedure: Chest wall reconstruction

Interventions

  • Procedurechest wall reconstruction

    Chest wall reconstruction was performed using PMMA bone cement molded intraoperatively over a polypropylene mesh to form a rigid prosthesis. The construct was fixed to the adjacent ribs with nonabsorbable sutures or wires.

  • ProcedureChest wall reconstruction

    chest wall reconstruction was achieved using twisted stainless steel wires (No. 05) anchored to the adjacent ribs or sternum, creating a flexible rib framework. The wires were tightened in a crisscross fashion to provide stable yet dynamic support.

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Assessment:

    Postoperative analgesia followed a standardized multimodal protocol of intravenous paracetamol and NSAIDs unless contraindicated, supplemented with intravenous morphine (0.05-0.1 mg/kg) as required. Thoracic epidural or paravertebral blockade was used selectively based on resection extent or anesthetist preference. Rescue analgesia was administered when VAS pain scores were ≥4 at rest or ≥5 during movement.

    Time frame: 24 hours, 48 hours and 7 days post-operatively

Secondary outcomes

  1. Chest Wall Movement

    Chest wall function was evaluated clinically at discharge, at 1-month follow-up, and at 3-month follow-up by the operating surgeon or thoracic fellow, and patients who underwent surgery earlier in the study period remain under active surveillance, providing a total follow-up duration of up to two years. Assessment included inspection for paradoxical movement during quiet and deep breathing and measurement of axillary excursion when feasible. Normal chest movement was defined as symmetrical expansion or ≥3 cm axillary excursion. Restricted movement was defined as \<3 cm excursion, ≥25% asymmetry relative to the contralateral side, or patient-reported limitation.

    Time frame: 1 month and 3 months post-operatively

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 71 months is above that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2026
First posted
Jan 13, 2026
StartActual
Jan 1, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07338006
Lead sponsor
University of Health Sciences Lahore
Responsible party
Zeeshan Sarwar (Doctor, University of Health Sciences Lahore) — Principal investigator
First posted
Jan 13, 2026
Start date
Jan 1, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jan 13, 2026

Study contacts

Muhammad Shoaib Nabi, FCPS
Contact
zeeshan.sarwar195@gmail.com
+92 3214347410

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion